Revolutionizing the treatment of mental health

Diamond is the first psychedelic-focused biotech company to explore microdosed, sub-perceptual dosing of psychedelics for the treatment of mental health disorders. The company’s lead candidate is a microdosed form of psilocybin for treating social anxiety disorder. The team is accompanied by top researchers in the field of psychedelic medicine, and an experienced management team with a background in life sciences investing and cannabis operations.